Adjuvant vs Surgery Only in Early-stage Recurrent NPC

PHASE3RecruitingINTERVENTIONAL
Enrollment

176

Participants

Timeline

Start Date

June 25, 2024

Primary Completion Date

June 30, 2028

Study Completion Date

June 30, 2028

Conditions
Recurrent Nasopharyngeal Carcinoma
Interventions
DRUG

Immunotherapy,Toripalimab Injection

Patients in the experimental group would be implemented with adjuvant Immunotherapy and chemotherapy after endoscopic surgery. Four to six cycles chemotherapy and 10 cycles immunotherapy,or until unacceptable side effects.

DRUG

Chemotherapy,Gemcitabine based regimen

Patients in the experimental group would be implemented with adjuvant Immunotherapy and chemotherapy after endoscopic surgery. Four to six cycles chemotherapy and 10 cycles immunotherapy,or until unacceptable side effects.

Trial Locations (7)

200031

RECRUITING

Eye& ENT Hospital, Fudan University, Shanghai

Unknown

NOT_YET_RECRUITING

Fujian Medical University Union Hospital, Fuzhou

RECRUITING

The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning

RECRUITING

Changhai Hospital, Shanghai

NOT_YET_RECRUITING

Shanghai Sixth People's Hospital, Shanghai

NOT_YET_RECRUITING

Shanghai Zhongshan Hospital, Shanghai

NOT_YET_RECRUITING

Shenzhen Second People's Hospital, Shenzhen

All Listed Sponsors
collaborator

Shanghai Zhongshan Hospital

OTHER

collaborator

Shanghai 6th People's Hospital

OTHER

collaborator

Changhai Hospital

OTHER

collaborator

Fujian Medical University Union Hospital

OTHER

collaborator

People's Hospital of Guangxi Zhuang Autonomous Region

OTHER

collaborator

Shenzhen Second People's Hospital

OTHER

lead

Eye & ENT Hospital of Fudan University

OTHER